Adaptimmune Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $13,677 | $7,285 | $3,222 | $40,901 |
Gross Profit | 11,176 | 6,406 | 3,222 | 40,901 |
EBITDA | -26,257 | -42,662 | -67,974 | -12,859 |
EBIT | -28,766 | -45,128 | -70,809 | -15,677 |
Net Income | -30,340 | -47,584 | -74,215 | -17,617 |
Net Change In Cash | 13,677 | 7,285 | 3,222 | 40,901 |
Free Cash Flow | -34,855 | -66,592 | -35,377 | -54,886 |
Cash | 26,061 | 41,054 | 91,139 | 116,741 |
Basic Shares | 264,087 | 257,026 | 255,942 | 255,768 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $178,032 | $60,281 | $27,148 | $6,149 |
Gross Profit | 177,962 | 50,423 | -100,578 | -104,941 |
EBITDA | -52,665 | -128,198 | -155,593 | -155,679 |
EBIT | -63,894 | -138,038 | -161,664 | -162,245 |
Net Income | -70,814 | -113,871 | -165,456 | -158,090 |
Net Change In Cash | 178,032 | 60,281 | 27,148 | 6,149 |
Cost of Revenue | 89,817 | |||
Free Cash Flow | -75,926 | -145,760 | -171,509 | 1,948 |
Cash | 91,139 | 143,991 | 108,033 | 149,948 |
Basic Shares | 252,301 | 201,073 | 161,207 | 155,805 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.02 |
2025-03-31 | -$0.18 |
2024-12-31 | -$0.05 |
